The fibrin-specific plasminogen activator – which is already sold as Metalyse and TNKase for patients with suspected acute myocardial infarction – was being tested in phase 3 stroke trials ...
Stroke is a heterogeneous syndrome caused by multiple disease mechanisms, but all result in a disruption of cerebral blood flow with subsequent tissue damage. This review covers the mechanisms ...